PulseSight Therapeutics announces the initiation of the clinical plan of PST-611, Transferrin Vectorized Therapy for dry AMD/Geographic Atrophy
January 14, 2025 03:00 ET | Source: PulseSight Therapeutics S.A.S PARIS, Jan.…
January 14, 2025 03:00 ET | Source: PulseSight Therapeutics S.A.S PARIS, Jan.…
Sign in to your account